TELA Bio, Inc.: updates and filings

TELANASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$0.69

November 20, 2026Market cap $40M

What Ploutos Investor adds for TELA Bio

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 9 fiscal years, from 2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 81 daysAround Feb 10, 2027 · for Q4 2026

last Nov 10, 2026next Feb 10, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 25, 2026 latest annualNov 10, 2026 latest quarterly
  • Nov 18, 2026Filing
    FormEFFECT
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 10, 2026Shelf registration for future offerings
    FormS-3
  • Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 10, 2026Results of operations
    Form8-K
  • Oct 8, 2026Shareholder vote
    Form8-K
  • Oct 6, 2026Other material events
    Form8-K
  • Oct 5, 2026Other material events
    Form8-K
  • Sep 29, 2026Material agreement entered
    Form8-K
  • Sep 18, 2026Delisting notice
    Form8-K
  • Sep 14, 2026Annual meeting proxy statement
    FormDEF 14A
  • Sep 4, 2026Preliminary proxy statement
    FormPRE 14A
  • Aug 31, 2026Restructuring costs, officer or director change, Regulation FD disclosure
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 13, 2026Officer or director change (amendment)
    Form8-K/A
  • Aug 11, 2026Shares registered for employees
    FormS-8
  • Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 11, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 10, 2026Results of operations
    Form8-K
  • Aug 4, 2026Shares registered for employees
    FormS-8
  • Aug 4, 2026Officer or director change
    Form8-K
  • Jun 11, 2026Officer or director change, shareholder vote
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 6, 2012.

The full analysis

What do TELA Bio's filings show?

The filings are where every one of TELA Bio's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.